scholarly journals Cystic Fibrosis Pulmonary Exacerbation – Natural History, Causative Factors and Management

10.5772/54336 ◽  
2013 ◽  
Author(s):  
Iara Maria ◽  
Nabil Jar
Keyword(s):  
Cystic Fibrosis ◽  
Natural History ◽  
Pulmonary Exacerbation ◽  
Causative Factors ◽  
Cystic Fibrosis Pulmonary Exacerbation

scholarly journals Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation

2015 ◽  
Vol 50 (9) ◽  
pp. 869-877 ◽  
Author(s):  
Theresa A. Laguna ◽  
Cavan S. Reilly ◽  
Cynthia B. Williams ◽  
Cole Welchlin ◽  
Chris H. Wendt
Keyword(s):  
Cystic Fibrosis ◽  
Pulmonary Exacerbation ◽  
Plasma Biomarkers ◽  
Metabolomics Analysis ◽  
Cystic Fibrosis Pulmonary Exacerbation

scholarly journals Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset

2011 ◽  
Vol 11 (2) ◽  
pp. 197-206 ◽  
Author(s):  
Geraint B Rogers ◽  
Lucas R Hoffman ◽  
Matt W Johnson ◽  
Nicole Mayer-Hamblett ◽  
Jürgen Schwarze ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Pulmonary Exacerbation ◽  
Cystic Fibrosis Pulmonary Exacerbation ◽  
Early Indicators

Use of the Modified Shuttle Walk Test During Inpatient Pediatric Cystic Fibrosis Pulmonary Exacerbation Treatment

2018 ◽  
pp. 1
Author(s):  
Shruti M. Paranjape ◽  
Kathryn A. Carson ◽  
Seifu M. Demissie ◽  
Holly Loosen ◽  
Kerry Vela ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Pulmonary Exacerbation ◽  
Walk Test ◽  
Cystic Fibrosis Pulmonary Exacerbation

scholarly journals 1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S749-S750
Author(s):  
Mahmoud Shorman ◽  
ghassan wadi ◽  
Michael P Veve
Keyword(s):  
Cystic Fibrosis ◽  
Health Insurance ◽  
Adverse Drug Events ◽  
Pulmonary Exacerbation ◽  
Efficacy And Safety ◽  
Research Support ◽  
Study Objective ◽  
Clinical Worsening ◽  
Cystic Fibrosis Pulmonary Exacerbation ◽  
Infection Recurrence

Abstract Background Telavancin (TLV) is an advanced generation lipoglycopeptide with activity against methicillin-resistant Staphylococcus aureus (MRSA), but there are limited patient outcomes in the setting of cystic fibrosis pulmonary exacerbation (CFPE). The study objective was to compare the efficacy and safety of TLV to vancomycin (VAN) in CFPE. Methods Retrospective cohort conducted from 1/2011-6/2020. Inclusion criteria were: i) age ≥16 years, ii) hospitalized for CFPE with documented signs/symptoms of infection, iii) confirmed or suspected MRSA lower respiratory tract infection, iv) receipt of ≥48 hours of TLV or VAN. The primary outcome was 30-day CFPE-related readmission: infection recurrence, clinical worsening on treatment, or ADE requiring readmission. Secondary outcomes included adverse drug events (ADE) on therapy: acute kidney injury (AKI), rash, thrombocytopenias, cardiac abnormalities. Results 101 patients were included: 52 (52%) TLV, 49 (49%) VAN. The median (IQR) age was 22 (21-27) years, 50% were women, and 86% were Caucasian. The majority (84%) of patients had some federal health insurance; 19% had private health insurance. 93% of patients used a maintenance cystic fibrosis (CF) medication, and 35% had previous CF-therapy compliance concerns. 62% had a previous positive culture for MRSA; 22 (43%) TLV patients had documented MRSA infection on admission compared to 41 (84%) VAN (P< 0.001). The median (IQR) time to TLV initiation from admission was 1 (0.8-1.4) days. 13 patients were readmitted within 30-days due to CFPE; 8 (15)% TLV vs. 5 (10%) VAN (unAdjOR, 0.63; 95%CI, 0.19-2.1). Reasons for 30-day CFPE: TLV: 7 infection recurrence, 1 clinical worsening; VAN: 2 clinical worsening, 2 infection recurrence, 1 treatment-related ADE. When accounting for confounders, TLV was not associated with 30-day CFPE-related readmission (adjOR, 0.34, 95%CI, 0.1-1.2). Patients who received VAN more commonly experienced an ADE while hospitalized (18%), most notably AKI Conclusion TLV was associated with similar short-term clinical outcomes compared to VAN for treatment of CFPE due to confirmed or suspected MRSA. Patients who received TLV experienced fewer overall ADEs. Disclosures Mahmoud Shorman, MD, Cumberland (Grant/Research Support) ghassan wadi, MD, Cumberland (Grant/Research Support) Michael P. Veve, Pharm.D., Cumberland (Grant/Research Support)Paratek Pharmaceuticals (Research Grant or Support)

Sign in / Sign up

Export Citation Format

Share Document